PHOENIX
鳳凰城
,
，
March 10, 2026
2026年3月10日
/PRNewswire/ --
/PRNewswire/ --
三一資本公司
(Nasdaq:
（納斯達克：
TRIN
三因素指標
) (the 'Company'), a leading international alternative asset manager, today announced the commitment of $35 million in growth capital to Neuros Medical, Inc., a MedTech company focused on alleviating chronic post-amputation pain and restoring quality of life through neuromodulation technologies.
)（「公司」），一家領先的國際另類資產管理公司，今天宣佈向Neuros Medical, Inc.（一家專注於通過神經調節技術緩解慢性截肢後疼痛並恢復生活質量的醫療技術公司）投入3500萬美元的成長資本。
Neuros Medical's FDA-approved Altius Direct Electrical Nerve Stimulation System targets pain at its source by interrupting peripheral nerve signals responsible for phantom limb and residual limb pain. The system enables patients to activate therapy when needed, delivering targeted pain relief without relying on continuous medication.
Neuros Medical的FDA批准的Altius直接電神經刺激系統通過中斷導致幻肢痛和殘肢痛的外周神經信號，從源頭上針對疼痛進行治療。該系統允許患者在需要時啓動治療，提供針對性的疼痛緩解，而無需依賴持續用藥。
With treatment options historically limited to opioid-based therapies, Altius offers a differentiated alternative for post-amputation pain..
歷史上，治療選擇僅限於基於阿片類藥物的療法，而 Altius 為截肢後疼痛提供了與衆不同的替代方案。
'Neuros Medical has reached an important inflection point as their technology moves into real-world adoption. We are proud to continue to support their team as they expand access to a differentiated therapy that addresses a significant need within the life sciences ecosystem,' said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital..
「Neuros Medical的技術進入現實世界應用，這標誌着公司已經到達了一個重要的轉折點。我們很自豪能夠繼續支持他們的團隊，因為他們正在擴大一種差異化療法的使用範圍，這種療法滿足了生命科學生態系統中的重大需求，」Trinity Capital生命科學高級董事總經理Rob Lake表示。
This new capital will help Neuros Medical scale the commercialization of the Altius system and expand into new markets.
這筆新的資金將幫助Neuros Medical擴大Altius系統的商業化規模，並進軍新市場。
'We appreciate the continued partnership from Trinity,' said David Veino, President & CEO of Neuros Medical. 'The Trinity team has been an important partner prior to us achieving FDA approval and will remain an important partner as we expand. This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase of its mission to Relieve Pain and Restore Life for this underserved patient population.'.
「我們感謝Trinity的持續合作，」Neuros Medical總裁兼首席執行官David Veino表示。「Trinity團隊在我們獲得FDA批准之前一直是一個重要的合作伙伴，並且隨着我們的擴展，他們將繼續成為重要的合作伙伴。此次債務孖展的擴大為Neuros進入下一階段使命——緩解疼痛、恢復生活，服務這一未被充分滿足的患者羣體——提供了重要的財務靈活性。」
About Trinity Capital Inc.
關於三一資本公司
Trinity Capital Inc. (Nasdaq:
三一資本公司（納斯達克：
TRIN
三角指標
) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences.
）是一家國際另類資產管理公司，通過進入私人信貸市場為投資者尋求提供穩定回報。Trinity Capital 在五個不同的借貸領域中尋找並構建對資本充足、成長導向型公司的投資：發起人孖展、設備孖展、科技貸款、基於資產的貸款和生命科學。
As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe.
作為尋求定製債務解決方案的創新公司的長期、可信賴的合作伙伴，自2008年成立以來（截至2025年12月31日），Trinity Capital已在463項投資中部署了超過55億美元。Trinity Capital總部位於亞利桑那州鳳凰城，其專業團隊戰略性地分佈在美國和歐洲各地。
For more information on Trinity Capital, please visit .
有關三一資本的更多信息，請訪問 。
trinitycapital.com
三一資本.com
and stay connected to the latest activity via
並通過以下方式保持與最新活動的連接
領英
and
和
X
X
(@trincapital).
(@trincapital).
About Neuros Medical, Inc.
關於Neuros Medical公司
There are over two million patients in the U.S. living with limb loss and approximately 300,000 new lower limb amputations occurring every year. Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.
美國有超過兩百萬名截肢患者，每年大約發生30萬例新的下肢截肢。截肢後的疼痛包括幻肢痛和殘肢痛，影響高達80%的截肢者，這代表了一個顯著未滿足的醫療需求，因為現有的治療選擇有限，主要依賴阿片類藥物和加巴噴丁類藥物。
Neuros Medical is a privately held company and the maker of the Altius® Direct Electrical Nerve Stimulation System, which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to relieve pain and restore life for people suffering with post-amputation pain.
Neuros Medical是一傢俬人控股公司，也是Altius®直接電神經刺激系統的製造商，該系統已獲得FDA批准，適用於成年截肢者慢性難治性幻肢和殘肢下肢截肢後疼痛的輔助管理。我們的使命是為遭受截肢後疼痛的人們緩解疼痛，恢復生活。
We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them..
我們是一個由核心價值觀引導的充滿熱情的團隊，致力於為患者和照顧他們的醫療保健專業人員服務。
SOURCE Trinity Capital Inc.
來源：三一資本公司
21
21
%
%
more press release views with
更多新聞發布視圖與
Request a Demo
請求演示